Thromboprophylaxis in total hip-replacement surgery in Europe

Acenocoumarol, fondaparinux, dabigatran and rivaroxban

Natasa Ivanovic, Maarten Beinema, Jacobus R.B.J. Brouwers, Mark Naunton, Maarten J. Postma

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

This paper reviews the clinical and pharmacoeconomic studies that have been conducted within Europe for patients undergoing elective hip-replacement surgery. Additionally, we offer a perspective on the possible future clinical use of new agents in orthopedic surgery, such as dabigatran and BAY 59-7939 (rivaroxban). Low-molecular weight heparins are standard therapy for patients requiring thromboprophylaxis and, therefore, we compare these with the other agents: vitamin K antagonists, fondaparinux and the direct oral inhibitors (thrombin or factor Xa inhibitors). The most evidence on the cost-effectiveness and efficacy is available for the low-molecular weight heparins and fondaparinux. Their major limitation is that they require parenteral administration. Only fondaparinux has undergone an extensive pharmacoeconomic evaluation. The direct thrombin inhibitors and direct factor Xa inhibitors are possibly the drugs of the future, but it must be borne in mind that they are still in Phase III clinical trials and, therefore, their safety and efficacy profile is not completely understood, neither are the pharmacoeconomic aspects.

Original languageEnglish
Pages (from-to)49-58
Number of pages10
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume7
Issue number1
DOIs
Publication statusPublished - 1 Feb 2007
Externally publishedYes

Fingerprint

Acenocoumarol
Pharmaceutical Economics
Hip Replacement Arthroplasties
Antithrombins
Low Molecular Weight Heparin
Phase III Clinical Trials
Vitamin K
Cost-Benefit Analysis
Orthopedics
Hip
Safety
Pharmaceutical Preparations
Dabigatran
fondaparinux
Factor Xa Inhibitors
Therapeutics

Cite this

@article{84c518636d6549a58c70e04aad7773cc,
title = "Thromboprophylaxis in total hip-replacement surgery in Europe: Acenocoumarol, fondaparinux, dabigatran and rivaroxban",
abstract = "This paper reviews the clinical and pharmacoeconomic studies that have been conducted within Europe for patients undergoing elective hip-replacement surgery. Additionally, we offer a perspective on the possible future clinical use of new agents in orthopedic surgery, such as dabigatran and BAY 59-7939 (rivaroxban). Low-molecular weight heparins are standard therapy for patients requiring thromboprophylaxis and, therefore, we compare these with the other agents: vitamin K antagonists, fondaparinux and the direct oral inhibitors (thrombin or factor Xa inhibitors). The most evidence on the cost-effectiveness and efficacy is available for the low-molecular weight heparins and fondaparinux. Their major limitation is that they require parenteral administration. Only fondaparinux has undergone an extensive pharmacoeconomic evaluation. The direct thrombin inhibitors and direct factor Xa inhibitors are possibly the drugs of the future, but it must be borne in mind that they are still in Phase III clinical trials and, therefore, their safety and efficacy profile is not completely understood, neither are the pharmacoeconomic aspects.",
keywords = "Acenocoumarol, Cost-effectiveness, Dabigatran, Direct thrombin inhibitors, Fondaparinux, Rivaroxban, Thromboprophylaxis, Total hip replacement",
author = "Natasa Ivanovic and Maarten Beinema and Brouwers, {Jacobus R.B.J.} and Mark Naunton and Postma, {Maarten J.}",
year = "2007",
month = "2",
day = "1",
doi = "10.1586/14737167.7.1.49",
language = "English",
volume = "7",
pages = "49--58",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
publisher = "Taylor and Francis Ltd.",
number = "1",

}

Thromboprophylaxis in total hip-replacement surgery in Europe : Acenocoumarol, fondaparinux, dabigatran and rivaroxban. / Ivanovic, Natasa; Beinema, Maarten; Brouwers, Jacobus R.B.J.; Naunton, Mark; Postma, Maarten J.

In: Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 7, No. 1, 01.02.2007, p. 49-58.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Thromboprophylaxis in total hip-replacement surgery in Europe

T2 - Acenocoumarol, fondaparinux, dabigatran and rivaroxban

AU - Ivanovic, Natasa

AU - Beinema, Maarten

AU - Brouwers, Jacobus R.B.J.

AU - Naunton, Mark

AU - Postma, Maarten J.

PY - 2007/2/1

Y1 - 2007/2/1

N2 - This paper reviews the clinical and pharmacoeconomic studies that have been conducted within Europe for patients undergoing elective hip-replacement surgery. Additionally, we offer a perspective on the possible future clinical use of new agents in orthopedic surgery, such as dabigatran and BAY 59-7939 (rivaroxban). Low-molecular weight heparins are standard therapy for patients requiring thromboprophylaxis and, therefore, we compare these with the other agents: vitamin K antagonists, fondaparinux and the direct oral inhibitors (thrombin or factor Xa inhibitors). The most evidence on the cost-effectiveness and efficacy is available for the low-molecular weight heparins and fondaparinux. Their major limitation is that they require parenteral administration. Only fondaparinux has undergone an extensive pharmacoeconomic evaluation. The direct thrombin inhibitors and direct factor Xa inhibitors are possibly the drugs of the future, but it must be borne in mind that they are still in Phase III clinical trials and, therefore, their safety and efficacy profile is not completely understood, neither are the pharmacoeconomic aspects.

AB - This paper reviews the clinical and pharmacoeconomic studies that have been conducted within Europe for patients undergoing elective hip-replacement surgery. Additionally, we offer a perspective on the possible future clinical use of new agents in orthopedic surgery, such as dabigatran and BAY 59-7939 (rivaroxban). Low-molecular weight heparins are standard therapy for patients requiring thromboprophylaxis and, therefore, we compare these with the other agents: vitamin K antagonists, fondaparinux and the direct oral inhibitors (thrombin or factor Xa inhibitors). The most evidence on the cost-effectiveness and efficacy is available for the low-molecular weight heparins and fondaparinux. Their major limitation is that they require parenteral administration. Only fondaparinux has undergone an extensive pharmacoeconomic evaluation. The direct thrombin inhibitors and direct factor Xa inhibitors are possibly the drugs of the future, but it must be borne in mind that they are still in Phase III clinical trials and, therefore, their safety and efficacy profile is not completely understood, neither are the pharmacoeconomic aspects.

KW - Acenocoumarol

KW - Cost-effectiveness

KW - Dabigatran

KW - Direct thrombin inhibitors

KW - Fondaparinux

KW - Rivaroxban

KW - Thromboprophylaxis

KW - Total hip replacement

UR - http://www.scopus.com/inward/record.url?scp=33847055848&partnerID=8YFLogxK

U2 - 10.1586/14737167.7.1.49

DO - 10.1586/14737167.7.1.49

M3 - Review article

VL - 7

SP - 49

EP - 58

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

IS - 1

ER -